

Supporting information

Stereoselective Approach to Indolizidine and Pyrrolizidine Alkaloids: Total Synthesis of (-)-Lentiginosine, (-)-epi-Lentiginosine and Dihydroxypyrrolizidine

Shruti Vandana Kauloorkar,^a Vishwajeet Jha,^a Ganesh Jogdand^b and Pradeep Kumar,^{*a}.

^a Organic Chemistry Division, CSIR-National Chemical Laboratory (CSIR-NCL), Homi Bhabha Road, Pune – 411008, India. Fax +91-20-25902629; e-mail: pk.tripathi@ncl.res.in


^b NMR division, CSIR-National Chemical Laboratory (CSIR-NCL), Homi Bhabha Road, Pune – 411008, India.

Table of contents



1. ¹ H and ¹³ C spectra for compound 9	S3
2. ¹ H and ¹³ C spectra for compound 10	S4
3. ¹ H and ¹³ C spectra for compound 11	S5
4. ¹ H and ¹³ C spectra for compound 16	S6
5. ¹ H and ¹³ C spectra for compound 12	S7-S8

6. ^1H and ^{13}C spectra for compound 13	S9-S10
7. ^1H and ^{13}C spectra for compound 14	S11
8. ^1H and ^{13}C spectra for compound 15	S12
9. ^1H and ^{13}C spectra for compound 17	S13
10. ^1H and ^{13}C spectra for compound 3	S14
11. ^1H and ^{13}C spectra for compound 2	S15
12. ^1H and ^{13}C spectra for compound 4	S16
13. HRMS	S17-S19
14. HPLC Profiles	S20-S26



Dibenzyl (*R*)-1-(1,8-dihydroxyoctan-4-yl)hydrazine-1,2-dicarboxylate (9):





Dibenzyl 1-((2*R*,3*S*,4*R*)-8-((*tert*-butyldimethylsilyl)oxy)-1-ethoxy-2,3-dihydroxy-1-oxooctan-4-yl)hydrazine-1,2-dicarboxylate (10):




Dibenzyl 1-((2*S*,3*R*,4*R*)-8-((*tert*-butyldimethylsilyl)oxy)-1-ethoxy-2,3-dihydroxy-1-oxooctan-4-yl)hydrazine-1,2-dicarboxylate (11) :



Dibenzyl 1-((2*S*,3*R*,4*R*)-7-((*tert*-butyldimethylsilyl)oxy)-1-ethoxy-2,3-dihydroxy-1-oxoheptan-4-yl)hydrazine-1,2-dicarboxylate (16):




(3*R*,4*S*,5*R*)-5-(4-((*tert*-butyldimethylsilyl)oxy)butyl)-3,4-dihydropyrrolidin-2-one (12):





(3*R*,4*S*,5*R*)-5-(4-((*tert*-butyldimethylsilyl)oxy)butyl)-3,4-dihydropyrrolidin-2-one (12):

¹HNMR in Acetone-d₆:




(3*S*,4*R*,5*R*)-5-(4-((*tert*-butyldimethylsilyl)oxy)butyl)-3,4-dihydropyrrolidin-2-one (13):




(3*S*,4*R*,5*R*)-5-(4-((*tert*-butyldimethylsilyl)oxy)butyl)-3,4-dihydropyrrolidin-2-one (13):



¹HNMR in Acetone-d₆:




Dibenzyl 1-((2*S*,3*S*,4*R*)-1,2,3,8-tetrahydroxyoctan-4-yl)hydrazine-1,2-dicarboxylate (14):




Dibenzyl 1-((2*R*,3*R*,4*R*)-1,2,3,8-tetrahydroxyoctan-4-yl)hydrazine-1,2-dicarboxylate (15):




Dibenzyl 1-((2*R*,3*R*,4*R*)-1,2,3,7-tetrahydroxyheptan-4-yl)hydrazine-1,2-dicarboxylate (17):




(1*S*,2*S*,8*aR*)- octahydroindolizine-1,2-diol (3):




(1*R*,2*R*,8*aR*)-octahydroindolizine-1,2-diol (2):




(1*R*,2*R*,7*aR*)-hexahydro-1*H*-pyrrolizine-1,2-diol (4):




Lenti #471 RT: 2.10 AV: 1 NL: 2.89E8
T: FTMS + p ESI Full ms [100.00-700.00]




Lenti #482 RT: 2.14 AV: 1 NL: 1.35E9
T: FTMS + p ESI Full ms [100.00-700.00]



pyrrolizidine #497 RT: 2.21 AV: 1 NL: 7.99E9
T: FTMS + p ESI Full ms [100.00-700.00]




Enantiomeric excess of compound 8a and 8b:




Detector A - 1 (230nm)

Retention Time	C Area	Area %
13.300	8015760	95.313
16.225	394165	4.687
Totals	8409925	100.000

Project Leader : Dr. Pradeep kumar
 Column : Kromasil 5-AmyCoat(250x4.6 mm)
 Mobile Phase : IPA: Pet ether (10:90)
 Wavelength : 230nm
 Flow Rate : 0.5ml/min(396psi)
 conc. : 1mg/1.0 mL
 Inj vol- : 5ul






Detector A - 1 (254nm)

Retention Time	C Area	Area %
13.650	8063940	51.217
16.633	7680650	48.783
Totals	15744590	100.000


Project Leader : Dr.P.K.TRIPATHI
 Column :Kromasil 5-AmyCoat (250x4.6 mm)
 Mobile Phase :IPA: Pet Ether (10:90)
 Wavelength :254nm
 Flow Rate :0.5ml/min(29Kgf)
 conc. : 1mg/1.0 mL
 Inj vol- :5 ul




Detector A - 1 (254nm)

Retention Time	C Area	Area %
13.458	8409897	96.917
18.067	267556	3.083
Totals	8677453	100.000

Project Leader : Dr.P.K.TRIPATHI
 Column :Kromasil 5-AmyCoat (250x4.6 mm)
 Mobile Phase :IPA: Pet Ether (10:90)
 Wavelength :254nm
 Flow Rate :0.5ml/min(29Kgf)
 conc. : 1mg/1.0 mL
 Inj vol- :5 ul






Detector A - 1 (254nm)

Retention Time	C Area	Area %
13.567	3832587	50.664
18.017	3732153	49.336

Totals	7564740	100.000
--------	---------	---------

Project Leader : Dr.P.K.TRIPATHI
 Column :Kromasil 5-AmyCoat (250x4.6 mm)
 Mobile Phase :IPA: Pet Ether (10:90)
 Wavelength :254nm
 Flow Rate :0.5ml/min(29Kgf)
 conc. : 1mg/1.0 mL
 Inj vol- :5 ul


Diastereomeric ratio of compounds 10,11 and 16



Peak Quantitation: AREA

Calculation Method: AREA%

No.	RT	Height	Area	Area %
1	6.50	35587	659151	17.058
2	7.42	176691	3205137	82.942
		212278	3864288	100.000




Peak Quantitation: AREA

Calculation Method: AREA%

No.	RT	Height	Area	Area %
1	6.42	108336	1637966	59.800
2	7.43	67280	1101099	40.200
		175616	2739065	100.000

Chrom Type: HPLC Channel : 1




Peak Quantitation: AREA

Calculation Method: AREA%

No.	RT	Height	Area	Area %
1	6.42	108336	1637966	60.016
2	7.43	67091	1091240	39.984
		175427	2729206	100.000

Chrom Type: HPLC Channel : 1




Peak Quantitation: AREA

Calculation Method: AREA%


No.	RT	Height	Area	Area %
1	6.49	63111	1204084	73.668
2	7.50	24267	430392	26.332
		87378	1634476	100.000

Chrom Type: HPLC Channel : 1



No.	RT	Height	Area	Area %
1	6.09	56928	950097	77.155
2	7.22	13787	281318	22.845
		70715	1231415	100.000

Chrom Type: HPLC Channel : 1



Peak Quantitation: AREA

Calculation Method: AREA%

No.	RT	Height	Area	Area %
1	7.33	362	3613	0.228
2	8.23	83063	1579306	99.772
		83425	1582919	100.000